Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported an open-market sale of common stock tied to equity compensation. He sold 855 shares at $3.606 per share, with the transaction occurring to cover tax withholding obligations from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this sale, Militello directly holds 90,164 shares of common stock, including RSUs. The transaction represents a small portion of his overall reported holdings and is characterized in the footnotes as a tax-related disposition rather than a discretionary share sale.
RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Rocket Pharmaceuticals is offering certain eligible employees an exchange of outstanding employee stock options for replacement options under an Option Exchange. Eligible Options are grants under the 2014 Stock Option and Incentive Plan issued prior to 2025 with an exercise price of at least $3.52. As of April 24, 2026, there were Eligible Options to purchase 1,455,963 shares outstanding. Members of the board, executive officers at the EVP level and above, and certain advisers, consultants, contractors and former employees are not eligible. The number of shares underlying each replacement New Option will be determined by dividing the surrendered option's share count by an exchange ratio and rounding up, subject to the Offer to Exchange and related Terms of Election.